<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d305" origId="Dopamine"><sentence id="DrugDDI.d305.s0" origId="s0" text="Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine."><entity id="DrugDDI.d305.s0.e0" origId="s0.p1" charOffset="8-16" type="drug" text="dopamine"/><entity id="DrugDDI.d305.s0.e1" origId="s0.p4" charOffset="35-52" type="drug" text="monoamine oxidase"/><entity id="DrugDDI.d305.s0.e2" origId="s0.p14" charOffset="125-133" type="drug" text="dopamine"/><pair id="DrugDDI.d305.s0.p0" e1="DrugDDI.d305.s0.e0" e2="DrugDDI.d305.s0.e1" interaction="true"/><pair id="DrugDDI.d305.s0.p1" e1="DrugDDI.d305.s0.e0" e2="DrugDDI.d305.s0.e2" interaction="false"/><pair id="DrugDDI.d305.s0.p2" e1="DrugDDI.d305.s0.e1" e2="DrugDDI.d305.s0.e2" interaction="false"/></sentence><sentence id="DrugDDI.d305.s1" origId="s1" text="Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose."><entity id="DrugDDI.d305.s1.e0" origId="s1.p20" charOffset="36-50" type="drug" text="MAO inhibitors"/><entity id="DrugDDI.d305.s1.e1" origId="s1.p24" charOffset="108-120" type="drug" text="dopamine HCl"/><entity id="DrugDDI.d305.s1.e2" origId="s1.p28" charOffset="153-165" type="drug" text="dopamine HCl"/><pair id="DrugDDI.d305.s1.p0" e1="DrugDDI.d305.s1.e0" e2="DrugDDI.d305.s1.e1" interaction="false"/><pair id="DrugDDI.d305.s1.p1" e1="DrugDDI.d305.s1.e0" e2="DrugDDI.d305.s1.e2" interaction="false"/><pair id="DrugDDI.d305.s1.p2" e1="DrugDDI.d305.s1.e1" e2="DrugDDI.d305.s1.e2" interaction="false"/></sentence><sentence id="DrugDDI.d305.s2" origId="s2" text="Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow."><entity id="DrugDDI.d305.s2.e0" origId="s2.p35" charOffset="38-50" type="drug" text="dopamine HCl"/><entity id="DrugDDI.d305.s2.e1" origId="s2.p37" charOffset="55-63" type="drug" text="diuretic"/><pair id="DrugDDI.d305.s2.p0" e1="DrugDDI.d305.s2.e0" e2="DrugDDI.d305.s2.e1" interaction="true"/></sentence><sentence id="DrugDDI.d305.s3" origId="s3" text="Tricyclic antidepressants may potentiate the cardiovascular effects of adreneric agents."><entity id="DrugDDI.d305.s3.e0" origId="s3.p44" charOffset="0-25" type="drug" text="tricyclic antidepressants"/></sentence><sentence id="DrugDDI.d305.s4" origId="s4" text="Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol."><entity id="DrugDDI.d305.s4.e0" origId="s4.p50" charOffset="19-27" type="drug" text="dopamine"/><entity id="DrugDDI.d305.s4.e1" origId="s4.p53" charOffset="47-78" type="drug" text="beta-adrenergic blocking agents"/><entity id="DrugDDI.d305.s4.e2" origId="s4.p54" charOffset="88-99" type="drug" text="propranolol"/><entity id="DrugDDI.d305.s4.e3" origId="s4.p56" charOffset="104-114" type="drug" text="metoprolol"/><pair id="DrugDDI.d305.s4.p0" e1="DrugDDI.d305.s4.e0" e2="DrugDDI.d305.s4.e1" interaction="true"/><pair id="DrugDDI.d305.s4.p1" e1="DrugDDI.d305.s4.e0" e2="DrugDDI.d305.s4.e2" interaction="true"/><pair id="DrugDDI.d305.s4.p2" e1="DrugDDI.d305.s4.e0" e2="DrugDDI.d305.s4.e3" interaction="true"/><pair id="DrugDDI.d305.s4.p3" e1="DrugDDI.d305.s4.e1" e2="DrugDDI.d305.s4.e2" interaction="false"/><pair id="DrugDDI.d305.s4.p4" e1="DrugDDI.d305.s4.e1" e2="DrugDDI.d305.s4.e3" interaction="false"/><pair id="DrugDDI.d305.s4.p5" e1="DrugDDI.d305.s4.e2" e2="DrugDDI.d305.s4.e3" interaction="false"/></sentence><sentence id="DrugDDI.d305.s5" origId="s5" text="The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents."><entity id="DrugDDI.d305.s5.e0" origId="s5.p60" charOffset="56-68" type="drug" text="dopamine HCl"/><entity id="DrugDDI.d305.s5.e1" origId="s5.p63" charOffset="87-119" type="drug" text="alpha-adrenergic blocking agents"/><pair id="DrugDDI.d305.s5.p0" e1="DrugDDI.d305.s5.e0" e2="DrugDDI.d305.s5.e1" interaction="true"/></sentence><sentence id="DrugDDI.d305.s6" origId="s6" text="Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha-or beta-adrenergic blocking agents."><entity id="DrugDDI.d305.s6.e0" origId="s6.p64" charOffset="0-8" type="drug" text="Dopamine"/><entity id="DrugDDI.d305.s6.e1" origId="s6.p74" charOffset="89-120" type="drug" text="beta-adrenergic blocking agents"/><pair id="DrugDDI.d305.s6.p0" e1="DrugDDI.d305.s6.e0" e2="DrugDDI.d305.s6.e1" interaction="false"/></sentence><sentence id="DrugDDI.d305.s7" origId="s7" text="Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion."><entity id="DrugDDI.d305.s7.e0" origId="s7.p75" charOffset="0-14" type="drug" text="Butyrophenones"/><entity id="DrugDDI.d305.s7.e1" origId="s7.p77" charOffset="24-35" type="drug" text="haloperidol"/><entity id="DrugDDI.d305.s7.e2" origId="s7.p80" charOffset="41-55" type="drug" text="phenothiazines"/><entity id="DrugDDI.d305.s7.e3" origId="s7.p87" charOffset="142-150" type="drug" text="dopamine"/><pair id="DrugDDI.d305.s7.p0" e1="DrugDDI.d305.s7.e0" e2="DrugDDI.d305.s7.e1" interaction="false"/><pair id="DrugDDI.d305.s7.p1" e1="DrugDDI.d305.s7.e0" e2="DrugDDI.d305.s7.e2" interaction="false"/><pair id="DrugDDI.d305.s7.p2" e1="DrugDDI.d305.s7.e0" e2="DrugDDI.d305.s7.e3" interaction="true"/><pair id="DrugDDI.d305.s7.p3" e1="DrugDDI.d305.s7.e1" e2="DrugDDI.d305.s7.e2" interaction="false"/><pair id="DrugDDI.d305.s7.p4" e1="DrugDDI.d305.s7.e1" e2="DrugDDI.d305.s7.e3" interaction="true"/><pair id="DrugDDI.d305.s7.p5" e1="DrugDDI.d305.s7.e2" e2="DrugDDI.d305.s7.e3" interaction="true"/></sentence><sentence id="DrugDDI.d305.s8" origId="s8" text="Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine."><entity id="DrugDDI.d305.s8.e0" origId="s8.p88" charOffset="0-12" type="drug" text="Cyclopropane"/><entity id="DrugDDI.d305.s8.e1" origId="s8.p90" charOffset="16-51" type="drug" text="halogenated hydrocarbon anesthetics"/><entity id="DrugDDI.d305.s8.e2" origId="s8.p99" charOffset="201-209" type="drug" text="dopamine"/><pair id="DrugDDI.d305.s8.p0" e1="DrugDDI.d305.s8.e0" e2="DrugDDI.d305.s8.e1" interaction="false"/><pair id="DrugDDI.d305.s8.p1" e1="DrugDDI.d305.s8.e0" e2="DrugDDI.d305.s8.e2" interaction="true"/><pair id="DrugDDI.d305.s8.p2" e1="DrugDDI.d305.s8.e1" e2="DrugDDI.d305.s8.e2" interaction="true"/></sentence><sentence id="DrugDDI.d305.s9" origId="s9" text="This interaction appears to be related both to pressor activity and to beta-adrenergic stimulating properties of these catecholamines and may produce ventricular arrhythmias and hypertension."><entity id="DrugDDI.d305.s9.e0" origId="s9.p106" charOffset="47-55" type="drug" text="pressor"/></sentence><sentence id="DrugDDI.d305.s10" origId="s10" text="Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics."><entity id="DrugDDI.d305.s10.e0" origId="s10.p122" charOffset="66-78" type="drug" text="dopamine HCl"/><entity id="DrugDDI.d305.s10.e1" origId="s10.p125" charOffset="101-113" type="drug" text="cyclopropane"/><entity id="DrugDDI.d305.s10.e2" origId="s10.p127" charOffset="117-152" type="drug" text="halogenated hydrocarbon anesthetics"/><pair id="DrugDDI.d305.s10.p0" e1="DrugDDI.d305.s10.e0" e2="DrugDDI.d305.s10.e1" interaction="true"/><pair id="DrugDDI.d305.s10.p1" e1="DrugDDI.d305.s10.e0" e2="DrugDDI.d305.s10.e2" interaction="true"/><pair id="DrugDDI.d305.s10.p2" e1="DrugDDI.d305.s10.e1" e2="DrugDDI.d305.s10.e2" interaction="false"/></sentence><sentence id="DrugDDI.d305.s11" origId="s11" text="It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol."><entity id="DrugDDI.d305.s11.e0" origId="s11.p136" charOffset="70-78" type="drug" text="dopamine"/><entity id="DrugDDI.d305.s11.e1" origId="s11.p141" charOffset="148-159" type="drug" text="propranolol"/><pair id="DrugDDI.d305.s11.p0" e1="DrugDDI.d305.s11.e0" e2="DrugDDI.d305.s11.e1" interaction="true"/></sentence><sentence id="DrugDDI.d305.s12" origId="s12" text="The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension."><entity id="DrugDDI.d305.s12.e0" origId="s12.p143" charOffset="23-34" type="drug" text="vasopressor"/><entity id="DrugDDI.d305.s12.e1" origId="s12.p147" charOffset="70-80" type="drug" text="ergonovine"/><entity id="DrugDDI.d305.s12.e2" origId="s12.p150" charOffset="91-105" type="drug" text="oxytocic drugs"/><pair id="DrugDDI.d305.s12.p0" e1="DrugDDI.d305.s12.e0" e2="DrugDDI.d305.s12.e1" interaction="false"/><pair id="DrugDDI.d305.s12.p1" e1="DrugDDI.d305.s12.e0" e2="DrugDDI.d305.s12.e2" interaction="true"/><pair id="DrugDDI.d305.s12.p2" e1="DrugDDI.d305.s12.e1" e2="DrugDDI.d305.s12.e2" interaction="true"/></sentence><sentence id="DrugDDI.d305.s13" origId="s13" text="Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia."><entity id="DrugDDI.d305.s13.e0" origId="s13.p155" charOffset="18-27" type="drug" text="phenytoin"/><entity id="DrugDDI.d305.s13.e1" origId="s13.p158" charOffset="50-62" type="drug" text="dopamine HCl"/><pair id="DrugDDI.d305.s13.p0" e1="DrugDDI.d305.s13.e0" e2="DrugDDI.d305.s13.e1" interaction="true"/></sentence><sentence id="DrugDDI.d305.s14" origId="s14" text="It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed."><entity id="DrugDDI.d305.s14.e0" origId="s14.p173" charOffset="43-55" type="drug" text="dopamine HCl"/><entity id="DrugDDI.d305.s14.e1" origId="s14.p175" charOffset="73-82" type="drug" text="phenytoin"/><pair id="DrugDDI.d305.s14.p0" e1="DrugDDI.d305.s14.e0" e2="DrugDDI.d305.s14.e1" interaction="false"/></sentence></document>